Abstract:Cancer-related venous thromboembolism (VTE) is a major cause of death in cancer patients. Cancer cells can activate the host cell coagulation cascade and other pro-thrombotic characteristics. The treatment of cancer also serves as an additional mechanism that promotes VTE, leading to a higher risk of VTE in cancer patients compared to non-cancer patients. This article provides an overview of the relevant mechanisms and treatment methods for venous thromboembolism in cancer patients.